Discounted Cash Flow (DCF) Analysis Levered

Sesen Bio, Inc. (SESN)

$ 1.15
-0.10 (-8.00%)
Stock DCF: 0.44 | 1.15 | overvalue

Free Cash Flow

Year
A/P
2016
Actual
2017
Actual
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 29.980.420.010000000
Revenue (%)
Operating Cash Flow 2.62-17.76-22.83-37.52-30.84-0.09-0-0-0-0
Operating Cash Flow (%)
Capital Expenditure ---0-0.14-0.01-0-0-0-0-0
Capital Expenditure (%)
Free Cash Flow 2.62-17.76-22.83-37.66-30.84-0.09-0-0-0-0

Weighted Average Cost Of Capital

Share price $ 1.15
Beta 0.530
Diluted Shares Outstanding 117.89
Cost of Debt
Tax Rate -6.90
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 4.157
Total Debt -
Total Equity 135.57
Total Capital 135.57
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
2016
Actual
2017
Actual
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 29.980.420.010000000
Operating Cash Flow 2.62-17.76-22.83-37.52-30.84-0.09-0-0-0-0
Capital Expenditure ---0-0.14-0.01-0-0-0-0-0
Free Cash Flow 2.62-17.76-22.83-37.66-30.84-0.09-0-0-0-0
WACC
PV LFCF -24.77-39.22-30.84-0.09-0-0-0-0
SUM PV LFCF -0.09

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 4.16
Free cash flow (t + 1) -0
Terminal Value 0
Present Value of Terminal Value 0

Intrinsic Value

Enterprise Value -0.09
Net Debt -52.39
Equity Value 52.30
Shares Outstanding 117.89
Equity Value Per Share 0.44